이차 관해 후 Gemtuzumab Ozogamicin (MylotargⓇ) 단독 공고요법으로 장기 무질병 생존 중인 급성골수구성백혈병 1례: 종교적인 이유로 수혈과 조혈모세포 이식이 불가능하였던 예

Abstract

Despite improvement of long-term survival rate in pediatric acute myeloid leukemia (AML) during the last two decades, relapse/refractory disease remains a major obstacle to further improvement of prognosis. Moreover, there are only few therapeutic options which stimulate investigations for targeted, less toxic therapy. Gemtuzumab ozogamicin (GO, MylotargⓇ) is an anti-CD33 monoclonal antibody and there are ongoing studies evaluating safety and efficacy of this drug in relapsed/refractory AML patients. Still, the response rate is only 30% and the response does not last more than a year. We present a case of pediatric central nervous system relapsed AML who was treated with GO as a single consolidation therapy without stem cell transplantation because of religious belief and maintained CR status for more than 3 years.